Related Experiment Video
Updated: Jun 2, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF
Anne-Marie Baird1, Steven G Gray, Kenneth J O'Byrne
1Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College Dublin, Ireland.
Background:
IL-20 is a pleiotrophic member of the IL-10 family and plays a role in skin biology and the development of haematopoietic cells. Recently, IL-20 has been demonstrated to have potential anti-angiogenic effects in non-small cell lung cancer (NSCLC) by down regulating COX-2.
Methods:
The expression of IL-20 and its cognate receptors (IL-20RA/B and IL-22R1) was examined in a series of resected fresh frozen NSCLC tumours. Additionally, the expression and epigenetic regulation of this family was examined in normal bronchial epithelial and NSCLC cell lines. Furthermore, the effect of IL-20 on VEGF family members was examined.
Results:
The expression of IL-20 and its receptors are frequently dysregulated in NSCLC. IL-20RB mRNA was significantly elevated in NSCLC tumours (p<0.01). Protein levels of the receptors, IL-20RB and IL-22R1, were significantly increased (p<0.01) in the tumours of NSCLC patients. IL-20 and its receptors were found to be epigenetically regulated through histone post-translational modifications and DNA CpG residue methylation. In addition, treatment with recombinant IL-20 resulted in decreased expression of the VEGF family members at the mRNA level.
Conclusions:
This family of genes are dysregulated in NSCLC and are subject to epigenetic regulation. Whilst the anti-angiogenic properties of IL-20 require further clarification, targeting this family via epigenetic means may be a viable therapeutic option in lung cancer treatment.
Insights
Interleukin-20 (IL-20) and its receptors are dysregulated in non-small cell lung cancer (NSCLC) and are epigenetically regulated. Targeting this pathway may offer a new therapeutic strategy for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interleukin-20 (IL-20) is a cytokine involved in skin and hematopoietic cell development.
- IL-20 exhibits potential anti-angiogenic effects in non-small cell lung cancer (NSCLC) by downregulating COX-2.
- The role of IL-20 in NSCLC pathogenesis warrants further investigation.
Purpose of the Study:
- To investigate the expression and epigenetic regulation of the IL-20 family in NSCLC.
- To determine the effect of IL-20 on angiogenesis-related factors in NSCLC.
Main Methods:
- Examined IL-20 and its receptor expression (IL-20RA/B, IL-22R1) in NSCLC tumors and cell lines.
- Assessed epigenetic regulation via histone modifications and DNA methylation.
- Investigated the impact of IL-20 on VEGF family members.
Main Results:
- IL-20 and its receptors are frequently dysregulated in NSCLC, with elevated IL-20RB mRNA and protein levels.
- Epigenetic mechanisms, including histone modifications and DNA methylation, regulate IL-20 family expression.
- Recombinant IL-20 treatment reduced VEGF family member expression at the mRNA level.
Conclusions:
- The IL-20 gene family is epigenetically dysregulated in NSCLC.
- Epigenetic targeting of the IL-20 family presents a potential therapeutic strategy for lung cancer.
- Further research is needed to clarify the anti-angiogenic properties of IL-20 in NSCLC.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
TGF - β Signaling Pathway
